Download PDF
Dtsch Med Wochenschr 2010; 135(5): 203-206
DOI: 10.1055/s-0029-1244837
Kommentar | Commentary
Gastroenterologie, Pharmakologie
© Georg Thieme Verlag KG Stuttgart · New York

Clopidogrel und Protonenpumpeninhibitoren – Fluch oder Segen?

Clopidogrel and proton pump inhibitors – boon or bane?J. Labenz1 , 2 , W. Meyners1 , K-U. Petersen3
  • 1Medizinische Klinik mit Gastroenterologie und Kardiologie Ev. Jung-Stilling-Krankenhaus Siegen
  • 2Medizinische Fakultät der Universität Duisburg-Essen
  • 3 Medizinische Fakultät der RWTH Aachen
Further Information

Publication History

eingereicht: 23.10.2009

akzeptiert: 11.12.2009

Publication Date:
26 January 2010 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Protonenpumpenhemmer - Clopidogrel - Interaktion - Cytochrom P450 2C19

Keywords

protone pump inhibitors - Clopidogrel - drug interaction - Cytochrome P450 2C19

Literatur

  • 1 Adamopoulos A B, Sakizlis G N, Nasothimiou E G. et al . Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomised crossover study.  J Cardiovasc Pharmacol. 2009;  54 163-168
    Google Scholar
  • 2 Bonzel T, Erbel R, Hamm C W. et al . Perkutane Koronarinterventionen (PCI).  Clin Res Cardiol. 2008;  97 513-547
    Google Scholar
  • 3 CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events.  Lancet. 1996;  348 1329-1339
    Google Scholar
  • 4 Cuisset T, Frere C, Quilici J. et al . Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.  J Am Coll Cardiol. 2009;  54 1149-1153
    Google Scholar
  • 5 Fischbach W, Malfertheiner P, Hoffmann J C. et al . S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS).  Z Gastroenterol. 2009;  47 68-102
    Google Scholar
  • 6 Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors.  Brit Med J. 2008;  336 2-3
    Google Scholar
  • 7 Gilard M, Arnaud B, Cornily J C. et al . Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.  J Am Coll Cardiol. 2008;  51 256-260
    Google Scholar
  • 8 Grines C L, Bonow R O, Casey Jr D E . et al . Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents.  Circulation. 2007;  115 813-818
    Google Scholar
  • 9 Heidelbaugh J J, Goldberg K O, Inadomi J M. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI.  Am J Gastroenterol. 2009;  104 S27-S32
    Google Scholar
  • 10 Ho P M, Maddox T M, Wang L. et al . Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.  JAMA. 2009;  301 937-944
    Google Scholar
  • 11 Juurlink D N, Gomes T, Ko D T. et al . A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.  CMAJ. 2009;  180 713-718
    Google Scholar
  • 12 Lahner E, Annibale B, Delle Fave G. Systemic review: impaired drug absorption related to the co-administration of antisecretory therapy.  Aliment Pharmacol Ther. 2009;  29 1219-1229
    Google Scholar
  • 13 Li X Q, Andersson T B, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.  Drug Metabol Dispos. 2004;  32 821-827
    Google Scholar
  • 14 Mega J L, Close S AL, Wiviott S D. et al . Cytochrome P-450 polymorphisms and response to Clopidogrel.  N Engl J Med. 2009;  360 354-362
    Google Scholar
  • 15 Ng F H, Lam K F, Chang C M. et al . Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.  Digestion. 2008;  77 173-177
    Google Scholar
  • 16 O’Donoghue M L, Braunwald E, Antman E M. et al . Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.  Lancet. 2009;  374 989-997
    Google Scholar
  • 17 Petersen K U. Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.  Arzneimittelforschung. 2009;  59 213-227
    Google Scholar
  • 18 Rosemary J, Adithan C. The pharmacogenetics of CYP 2C9 and CYP2C19: Ethnic variation and clinical significance.  Curr Clin Pharmacol. 2007;  2 93-109
    Google Scholar
  • 19 Sibbing D, Morath T, Stegherr J. et al . Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.  Thromb Haemost. 2009;  101 714-719
    Google Scholar
  • 20 Silber S, Borggrefe M, Böhm M. et al . Medikamente freisetzende Koronarstents (DES) und Medikamente freisetzende Ballonkatheter (DEB): Aktualisierung des Positionspapiers der DGK.  Clin Res Cardiol. 2008;  97 548-563
    Google Scholar
  • 21 Siller-Matula J M, Spiel A O, Lang I M. et al . Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.  Am Heart J. 2009;  157,148 e1-5
    Google Scholar
  • 22 Simon T, Verstuyft C, Mary-Krause M. et al . Genetic determinants of response to clopidogrel and cardiovascular events.  N Engl J Med. 2009;  360 363-375
    Google Scholar
  • 23 Taha A S, McCloskey C, Prasad R, Bezylak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.  Lancet. 2009;  374 119-125
    Google Scholar
  • 24 Wallentin N, Becker R C, Budaj A. et al . Ticagrelor versus Clopidogrel in patients with acute coronary syndromes.  N Engl J Med. 2009;  361 1045-1057
    Google Scholar

Prof. Dr. med. Joachim Labenz

Medizinische Klinik, Ev. Jung-Stilling-Krankenhaus, Akademisches Lehrkrankenhaus der Universität Bonn

Wichernstr. 40

57074 Siegen

Email: Joachim.Labenz@diakonie-sw.de

      >